The John Barnes School of Medicine at the University of Hawaii and Caldax Corporation recently published results of animal studies to evaluate the efficacy of anti-aging drugs.
The astaxanthin compound CDX-085 was developed by Cardax and can significantly improve FOXO3 gene expression. Previous studies have shown that this gene is related to longevity. "Every human body has the FOXO3 gene. This can help humans fight aging, but one-third of people have another FOXO3 related to human lifespan. Perhaps through this study, astaxanthin has been shown to activate the FOXO3 gene. , Making it a "longevity" version of FOXO3. Professor Bradley Wilcox said. In this preliminary study, astaxanthin was the first substance to test the ability of astaxanthin to activate FOXO3 genes in animals In this study, the researchers found that mice fed normal food or food containing low or high doses of astaxanthin compound CDX-085, while mice with high doses of astaxanthin compound had heart tissue. FOXO3 appeared. Increased gene expression.
Cardax CEO said: "This groundbreaking discovery by the University of Hawaii further supports the beneficial effects of astaxanthin on health and explains why certain healthcare groups place so much emphasis on astaxanthin." David Vatuer said . "I want to further confirm the anti-aging effect of astaxanthin in clinical trials."
“I’m very happy to work with Cardax on this very promising project. It can help delays. This is also a good example of Hawaii’s innovation program, where private companies and the government can work together to promote innovation, research, Education and economic diversification.” Vassilis L. Syrmos said.